26 April 2019
EMA/PDCO/196583/2019
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes of the meeting on 26-29 March 2019

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

26 March 2019, 14:00- 17:00, room 2D

27 March 2019, 08:30- 19:00, room 2D

28 March 2019, 08:30- 19:00, room 2D

29 March 2019, 08:30- 13:00, room 2D

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by Applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted and will be published on the EMA website.

1.3. Adoption of the minutes

The minutes of February 2019 PDCO meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Efpeglenatide - EMEA-001903-PIP01-15

Sanofi-aventis recherche et développement; Type 2 diabetes mellitus

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

During its March plenary meeting, the PDCO adopted a positive Opinion.

2.1.2. Dusquetide - EMEA-002306-PIP02-18

Soligenix UK Limited; Prevention of Severe Oral Mucositis

Day 120 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

A positive Opinion was adopted at Day 120.
In conclusion, the PDCO recommends granting a paediatric investigation plan for children from birth to less than 18 years of age and a deferral for the treatment of oral mucositis.

2.1.3. Fitusiran (synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues) - Orphan - EMEA-001855-PIP01-15

Genzyme Europe B.V.; Treatment of Haemophilia B, Treatment of Heamophilia A / Fitusiran is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in children aged ≥ 1 year with severe Haemophilia B, including patients who express neutralizing antibodies to exogenous factor IX substitution. Fitusiran is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in children aged ≥ 1 year with severe Haemophilia A, including patients who express neutralizing antibodies to exogenous factor VIII substitution

Day 120 opinion

Haematology-Hemostaseology

Summary of committee discussion:

A positive Opinion has been adopted by the PDCO.

2.1.4. Ustekinumab - EMEA-000311-PIP06-18

Janssen-Cilag International NV; ICD10: M32 Systemic lupus erythematosus (SLE) / Treatment of systemic lupus erythematosus (SLE)

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO endorsed at its March 2019 meeting a PIP for ustekinumab for the treatment of systemic lupus erythematosus (SLE) with a waiver and a deferral.

Chiesi Farmaceutici S.p.A.; Treatment of asthma / Regular treatment of asthma in patients not controlled with medium-high doses of inhaled corticosteroids and long-acting beta2-agonists

Day 120 opinion

Pneumology - Allergology

Summary of committee discussion:

A positive Opinion was adopted.

2.1.6. Atorvastatin / amlodipine / candesartan - EMEA-002520-PIP01-18

Midas Pharma GmbH; Treatment of essential hypertension (ICD9: 401, ICD10: I10), Treatment of Familial hypercholesterolemia (ICD9: 272.0, ICD10: E78.0) / For adults with hypertension and elevated cholesterol already controlled with candesartan, amlodipine and atorvastatin given concurrently at the same dose level as in the fixed dose combination (FDC), (substitution indication).

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for candesartan / atorvastatin / amlodipine for all subsets of the paediatric population (0 to less than 18 years of age) in the conditions of treatment of hypertension and treatment of hypercholesterolemia.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.7. Recombinant human lecithin cholesterol acyltransferase - Orphan - EMEA-002497-PIP01-18

AstraZeneca AB; Acute ST-Elevation Myocardial Infarction (STEMI)

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the assessment of this application and on the discussion on day 30, the PDCO agrees with the Applicant's request for a waiver. The PDCO adopted a positive Opinion on the granting of a product-specific waiver for recombinant human lecithin cholesterol acyltransferase for all subsets of the paediatric population (0 to 18 years of age) in the condition of acute ST elevation myocardial infarction (STEMI) on the ground that "the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible".

2.1.8. Inactivated patient's own (autologous) microorganism (Escherichia coli, Candida spp., Enterococcus spp., Streptococcus spp., Staphylococcus spp., Prevotella intermedia, Fusobacterium nucleatum and others) - EMEA-002442-PIP01-18

SymbioVaccin GmbH; Prevention and treatment of chronic or recurrent dermal or mucosal inflammation / Prevention and treatment of chronic or recurrent skin and/or mucosa inflammation in the urogenital, otorhinolaryngeal, bronchial, oral, gingiva or periodontal tract, resistant to treatment or not sufficiently treatable with topical or systemic antibiotics, antivirals, antifungals or anti-inflammatory compounds

Day 60 opinion

Dermatology / Pneumology - Allergology / Oto-rhino-laryngology / Uro-nephrology

Summary of committee discussion:

The PDCO view expressed at Day 30 was re-discussed and endorsed.
The PDCO recommends granting a waiver for inactivated patient's own (autologous) microorganism (Escherichia coli, Candida spp., Enterococcus spp., Streptococcus spp., Staphylococcus spp., Prevotella intermedia, Fusobacterium nucleatum and others) for all subsets of the paediatric population (0 to 18 years of age) in the conditions of 'Treatment and prevention of bacterial upper respiratory tract infections', 'Treatment and prevention of dermatitis and eczema' and 'Treatment and prevention of genitourinary tract infections and inflammations'.

2.1.9. Seladelpar - Orphan - EMEA-002527-PIP01-18

CymaBay Ireland Limited; Treatment of primary biliary cholangitis

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

Based on the assessment of this application, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for seladelpar for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of primary biliary cholangitis.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO identified cholestatic diseases affecting children as an unmet need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.10. Humanized antibody targeting B cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F - Orphan - EMEA-002468-PIP02-18

GlaxoSmithKline Trading Services; Treatment of multiple myeloma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO discussed this procedure at Day 60 during the March 2019 plenary.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for humanized antibody targeting B cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of multiple myeloma.
The PDCO emphasises that the granting of a waiver for the condition mentioned above

should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.11. Niraparib - Orphan - EMEA-002268-PIP03-18

Janssen Research & Development; Treatment of prostate malignant neoplasms

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO discussed this procedure. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for niraparib for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'Treatment of prostate malignant neoplasms'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a pae diatric need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.12. Carfilzomib - Orphan - EMEA-001806-PIP03-18

Amgen Europe BV; Treatment of multiple myeloma

Day 60 opinion

Oncology / Haematology-Hemostaseology

Summary of committee discussion:

The PDCO discussed this procedure at Day 60 during the March 2019 plenary.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for carfilzomib for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of multiple myeloma.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.13. Amoxicillin - EMEA-002548-PIP01-19

Micro Labs GmbH; Adults / Pantoprazole/clarithromycin/amoxicillin is used for combination therapy for the eradication of Helicobacter pylori in patients with peptic ulceration, with the aim of reducing the frequency of recurrence of duodenal ulcer disease (ulcera duodeni) and gastric ulcer (ulcer ventriculi) caused by this pathogen.

Day 60 opinion

Other

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for pantoprazole / amoxicillin / clarithromycin (in a combination pack) for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'Treatment of helicobacter pylori infections'.

2.1.14. Clarithromycin - EMEA-002549-PIP01-19

Micro Labs GmbH; Adults / Pantoprazole/clarithromycin/amoxicillin is used for combination therapy for the eradication of Helicobacter pylori in patients with peptic ulceration, with the aim of reducing the frequency of recurrence of duodenal ulcer disease (ulcera duodeni) and gastric ulcer (ulcer ventriculi) caused by this pathogen.

Day 60 opinion

Other

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for pantoprazole / amoxicillin / clarithromycin (in a combination pack) for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of helicobacter pylori infections.

2.1.15. Colecalciferol - EMEA-002553-PIP01-19

Pharma Patent Kft.; Treatment of osteoporosis

Day 60 opinion

Other

Summary of committee discussion:

The PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for colecalciferol for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of osteoporosis, on grounds of lack of significant therapeutic benefit over existing treatments.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.16. Ibandronic acid - EMEA-002331-PIP01-18

Pharma Patent Kft.; Treatment of osteoporosis

Day 60 opinion

Other

Summary of committee discussion:

The PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for ibandronic acid for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of osteoporosis, on grounds of lack of significant therapeutic benefit over existing treatments.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle, according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.17. Pantoprazole - EMEA-002512-PIP01-18

Micro Labs GmbH; Adults / Pantoprazole/clarithromycin/amoxicillin is used for combination therapy for the eradication of Helicobacter pylori in patients with peptic ulceration, with the aim of reducing the frequency of recurrence of duodenal ulcer disease (ulcera duodeni) and gastric ulcer (ulcer ventriculi) caused by this pathogen.

Day 60 opinion

Other

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for pantoprazole / amoxicillin / clarithromycin (in a combination pack) for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of helicobacter pylori infections.

2.1.18. Olopatadine hydrochloride / mometasone furoate (as the monohydrate) - EMEA-002514-PIP01-18

Treatment of allergic rhinitis / rhino-conjunctivitis

Day 60 opinion

Oto-rhino-laryngology

Summary of committee discussion:

The PDCO adopted a positive Opinion.

2.1.19. EMEA-002398-PIP01-18

SFL Regulatory Services GmbH; Cystic fibrosis / Treatment of cystic fibrosis in individuals with cystic fibrosis who are homozygous for the F508del mutation and are receiving treatment with a cystic fibrosis transmembrane conductance regulator (CFTR) modulator

Day 120 opinion

Pneumology - Allergology

Summary of committee discussion:

The Committee adopted a positive Opinion for the treatment of cystic fibrosis in individuals who are homozygous for the F508del mutation and are receiving treatment with a CFTR modulator.

2.1.20. Budesonide / salbutamol sulfate - EMEA-002533-PIP01-18

AstraZeneca AB; Treatment of asthma / as-needed treatment or prevention of bronchoconstriction in children aged 6 years and older with reversible obstructive airway disease / The reduction of exacerbations in children aged 6 years and older with asthma

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO recommends granting a waiver on its own motion for budesonide / salbutamol sulfate for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'Treatment of asthma' on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

Janssen-Cilag International NV; Treatment of HIV-1 infection

Day 30 letter

Infectious Diseases

Summary of committee discussion:

The PDCO discussed the completed study and considered that it is compliant with the latest Agency's Decision (P/0006/2019) of 3 January 2019.

2.2.2. Potassium hydrogen carbonate / potassium citrate monohydrated - EMEA-C1-001357-PIP01-12-M02

ADVICENNE; Treatment of renal tubular acidosis

Day 30 letter

Uro-nephrology

Summary of committee discussion:

The PDCO discussed the completed study(ies) and considered that these are compliant with the latest Agency's Decision (P/0355/2018) of 7/12/2018.
The PDCO finalised this partially completed compliance procedure on 29 March 2019.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Angiotensin II - EMEA-001912-PIP02-16-M02

La Jolla Pharmaceutical II B.V.; Hypotension associated with distributive or vasodilatory shock

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0130/2018 of 06/04/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Omecamtiv mecarbil - EMEA-001696-PIP01-14-M01

Amgen Europe B.V.; Treatment of heart failure / Treatment of chronic heart failure New York Association (NYHA) class II-IV with systolic dysfunction, in children and adolescents 6 to <18 years, in combination with standard pharmacological therapy, including angiotensin converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers, and/or beta-blockers

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the review of the clarifications submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0197/2015 of 04 September 2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Asfotase alfa - Orphan - EMEA-000987-PIP01-10-M04

Alexion Europe SAS; Hypophosphatasia / Treatment of hypophosphatasia

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be

accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0204/2017 of 09/08/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. Deferiprone - Orphan - EMEA-001126-PIP01-10-M03

Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) - Coordinator for DEEP Project (HEALTH-F4-2010-261483); treatment of chronic iron overload requiring chelation therapy / treatment of iron overload in paediatric patients affected by haemoglobinopathies requiring chronic transfusions and iron chelation

Day 60 opinion

Haematology-Hemostaseology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0357/2016 of 21/12/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Ravulizumab - Orphan - EMEA-002077-PIP01-16-M02

Alexion Europe SAS; Paroxysmal nocturnal haemoglobinuria / Treatment of paroxysmal nocturnal haemoglobinuria

Day 60 opinion

Haematology-Hemostaseology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that only part of the proposed changes could be accepted.
The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0356/2017 of 1 December 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Baricitinib - EMEA-001220-PIP01-11-M05

Eli Lilly and Company Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis) / Treatment of juvenile idiopathic arthritis (JIA), Treatment of JIA-associated uveitis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0157/2018 of 15/06/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Adalimumab - EMEA-000366-PIP02-09-M06

AbbVie Limited; Ulcerative Colitis / Treatment of moderate to severe ulcerative colitis

Day 60 opinion

Immunology-Rheumatology-Transplantation / Ophthalmology / Dermatology / Gastroenterology-Hepatology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0342/2017 of 10 November 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. Relebactam monohydrate / cilastatin sodium / imipenem monohydrate - EMEA-001809-PIP01-15-M01

Merck Sharp & Dohme (Europe), Inc.; Treatment of bacterial infections caused by gram-negative bacteria

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO considered that the condition name could remain 'Treatment of Gram-negative bacterial infections' at the moment. However, the name should be amended to 'Treatment of infections caused by aerobic Gram-negative organisms' in a future modification. The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0163/2016 of 15 June 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.9. Onasemnogene abeparvovec - Orphan - EMEA-002168-PIP01-17-M01

AveXis Netherlands B.V.; Treatment of spinal muscular atrophy / Treatment of spinal muscular atrophy Type 1

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that only some of the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0272/2018 of 13 August 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.10. Quizartinib - Orphan - EMEA-001821-PIP01-15-M03

Daiichi Sankyo Europe GmbH; Treatment of acute myeloid leukaemia (AML) / For the treatment of paediatric patients aged from 1 month to less than 18 years of age with newly diagnosed AML with FLT3-ITD mutations, For the treatment of paediatric patients aged from 1 month to less than 18 years of age with refractory or relapsed AML with FLT3-ITD mutations after failure of front line intensive chemotherapy regimen, in combination with standard chemotherapy.

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0268/2018 of 16/08/2018)
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.11. Ruxolitinib (phosphate) - EMEA-000901-PIP03-16-M01

Novartis Europharm Limited; Acute Graft versus Host Disease / Treatment of acute Graft versus Host Disease (GvHD) after allogeneic hematopoietic stem cell transplantation (alloSCT) in paediatric patients aged 28 days and above

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0349/2017 of 01/12/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO

Opinion.

2.3.12. Gilteritinib (as fumarate) - Orphan - EMEA-002064-PIP01-16-M01

Astellas Pharma Europe B.V.; Treatment of acute myeloid leukemia (AML) / Treatment of patients from 6 months to less than 18 years of age with relapsed or refractory FLT3/ITD positive acute myeloid leukaemia or newly-diagnosed FLT3/ITD positive acute myeloid leukaemia

Day 60 opinion

Oncology / Haematology-Hemostaseology

Summary of committee discussion:

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0006/2018 of 19 January 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.13. Clostridium botulinum neurotoxin type A, free from complexing proteins - EMEA-001039-PIP02-12-M03

Merz Pharmaceuticals GmbH; Treatment of sialorrhea / Treatment of chronic troublesome sialorrhea associated with neurological conditions (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescents aged 2 – 17 years.

Day 60 opinion

Ophthalmology / Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0156/2016 of 15/06/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.14. Agomelatine - EMEA-001181-PIP01-11-M04

Les Laboratoires Servier; Major Depressive Episodes

Day 60 opinion

Psychiatry

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could not be accepted.
The PDCO therefore adopted a negative Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0191/2016 of 15/07/2016).

2.3.15. Finerenone - EMEA-001623-PIP01-14-M02

Bayer AG; Chronic Kidney Disease / Treatment of chronic kidney disease associated with proteinuria in addition to a therapy with angiotensin converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB)

Day 60 opinion

Uro-nephrology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan and on the discussion on day 30, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0362/2016 of 21 December 2019).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.4. Opinions on Re-examinations

2.4.1. Chemically modified recombinant human sulfamidase - Orphan - EMEA-002380-PIP01-18

Swedish Orphan Biovitrum AB (publ); Mucopolysaccharidosis type IIIA (MPS IIIA)

Day 30 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The Paediatric Committee endorsed the grounds for re-examination and the changes requested by the Applicant.

The PIP Opinion is modified.

2.5. Opinions on Review of Granted Waivers

No items

2.6. Finalisation and adoption of opinions

No items

2.7. Partial Compliance Checks completed by EMA

For the following partial compliance checks, no need to refer them to PDCO Committee for discussion, were identified by the PME coordinator and PDCO Rapporteur. The PDCO has been informed in writing.

2.7.1. B (Victoria lineage)/A (H1N1)/B (Yamagata lineage)/A (H3N2) - EMEA-C2-001715-PIP01-14-M02

Seqirus Netherlands B.V.; Prevention of influenza / Active immunisation against influenza in children of 6 to less than 72 months of age / Active immunisation of influenza in elderly subjects of 65 years and older

Day 1 letter

Vaccines

Summary of committee discussion:

Studies are hereby confirmed to be compliant as set out in the EMA's Decision P/0057/2019 of 25 February 2019.

2.7.2. Cobicistat - EMEA-C1-000969-PIP01-10-M04

Gilead Sciences Ireland UC; Treatment of human immunodeficiency virus type-1 (HIV-1) infection

Day 30 letter

Infectious Diseases

Summary of committee discussion:

The study is hereby confirmed to be compliant as set out in the EMA's Decision (P/0060/2017) of 17 March 2017.

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

3. Discussion of applications

Some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Dihomo-γ-linolenic acid (DGLA) - EMEA-002364-PIP01-18

Treatment of atopic dermatitis / Treatment of moderate to severe atopic dermatitis

Day 90 discussion

Dermatology

BioMarin International Limited; Treatment of haemophila A / Treatment of patients with haemophilia A

Day 90 discussion

Haematology-Hemostaseology

3.1.3. Dexamethasone - EMEA-002423-PIP01-18

ICD10 H59.9 Postprocedural disorder of eye and adnexa, unspecified

Day 90 discussion

Ophthalmology

3.1.4. lentiviral vector containing the human ABCA4 gene for treatment of Stargardt's disease - Orphan - EMEA-002407-PIP01-18

Sanofi-Aventis Recherche & Développement; Treatment of inherited retinal disorders

Day 90 discussion

Ophthalmology

3.1.5. Glycerol / urea - EMEA-002511-PIP01-18

Treatment of atopic dermatitis / Treatment of dry skin, Prevention of relapse of atopic dermatitis

Day 60 discussion

Dermatology

3.1.6. EMEA-002501-PIP01-18

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency)

Day 60 discussion

Haematology-Hemostaseology

3.1.7. EMEA-002529-PIP01-18

Treatment of respiratory syncytial virus infection

Day 60 discussion

Infectious Diseases

3.1.8. Cladribine - EMEA-000383-PIP02-18

Treatment of multiple sclerosis / Adults and Paediatrics

Day 60 discussion

Neurology

3.1.9. Phenobarbital - EMEA-002532-PIP01-18

Epilepsy

Day 60 discussion

Neurology

3.1.10. Abemaciclib - EMEA-002342-PIP02-18

High grade glioma (HGG), Neuroblastoma (NBL) / Treatment of relapsed or refractory neuroblastoma in combination with irinotecan and temozolomide in paediatric patients, Treatment of newly diagnosed high grade glioma in combination with temozolomide in paediatric patients

Day 60 discussion

Oncology

3.1.11. Atogepant - EMEA-002530-PIP01-18

G43 Migraine / Prophylaxis of migraine

Day 60 discussion

Pain

3.1.12. (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3 cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride - Orphan - EMEA-002449-PIP02-18

BioCryst UK; Treatment of Hereditary Angioedema (HAE) / Treatment of HAE attacks, Prevention of HAE attacks

Day 60 discussion

Pneumology - Allergology

3.1.13. Tosatoxumab - Orphan - EMEA-002506-PIP01-18

Aridis Pharmaceuticals Inc; Pneumonia caused by Staphylococcus aureus / Same as adults

Day 60 discussion

Pneumology - Allergology

3.1.14. Ramipril / bisoprolol - EMEA-002531-PIP01-18

Treatment of chronic (systolic) heart failure (ICD10: I50.22), Treatment of coronary artery disease (ICD10: I25-1), Treatment of essential hypertension (ICD10: I10) / Treatment of hypertension with stable coronary artery disease and those with stable chronic heart failure with reduced systolic left ventricular function in adult patients adequately controlled with bisoprolol and ramipril given concurrently at the same dose level (substitution indication).

Day 30 discussion

Cardiovascular Diseases

3.1.15. Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII - Orphan - EMEA-002472-PIP02-19

Krystal Biotech, Inc.; Dystrophic epidermolysis bullosa

Day 30 discussion

Dermatology

3.1.16. Human monoclonal IgG2 antibody against tissue factor pathway inhibitor - Orphan - EMEA-002498-PIP01-18

Bayer AG; Treatment of haemophilia A, Treatment of haemophilia B

Day 30 discussion

Haematology-Hemostaseology

3.1.17. Sutimlimab - Orphan - EMEA-002542-PIP01-18

Bioverativ Inc; Treatment of primary Cold Agglutinin Disease

Day 30 discussion

Haematology-Hemostaseology

3.1.18. EMEA-002528-PIP01-19

Chronic idiopathic arthritis / Treatment of juvenile idiopathic arthritis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.19. Ibrexafungerp citrate - EMEA-002535-PIP01-18

Vulvovaginal candidiasis

Day 30 discussion

Infectious Diseases

3.1.20. Iclaprim Mesylate - EMEA-002391-PIP02-19

Infection with Gram-positive bacteria

Day 30 discussion

Infectious Diseases

Deciphera Pharmaceuticals LLC; Treatment of gastrointestinal stromal tumours

Day 30 discussion

Oncology

3.1.22. Abemaciclib - EMEA-002342-PIP03-18

Treatment of Breast Cancer

Day 30 discussion

Oncology

3.1.23. Capivasertib - EMEA-002551-PIP01-18

Prostate Cancer, Breast cancer

Day 30 discussion

Oncology

3.1.24. Tisotumab vedotin - EMEA-002522-PIP01-18

Treatment of cervical cancer

Day 30 discussion

Oncology

3.1.25. Trilaciclib - EMEA-002534-PIP02-19

Prevention of chemotherapy induced myelosuppression / Prevention of chemotherapy induced myelosuppression

Day 30 discussion

Oncology

3.1.26. EMEA-002503-PIP01-18

Biochemical recurrence of prostate cancer

Day 30 discussion

Oncology / Uro-nephrology

3.1.27. Emiplacel - EMEA-002539-PIP01-18

Treatment of peripheral ischaemia

Day 30 discussion

Other

3.1.28. Human immunoglobulin G2 isotype antibody to IL-33R - EMEA-002515-PIP01-18

Treatment of asthma / Add-on therapy for the maintenance treatment for moderate-severe asthma

Day 30 discussion

Pneumology - Allergology

3.1.29. EMEA-002519-PIP02-18

Treatment of schizophrenia

Day 30 discussion

Psychiatry

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.2.1. Emicizumab - EMEA-C-001839-PIP01-15

Roche Registration GmbH; Treatment of Hereditary FVIII Deficiency

Day 30 discussion

Haematology-Hemostaseology

3.2.2. Turoctocog alfa - EMEA-C-000428-PIP01-08-M03

Novo Nordisk A/S; Treatment of hereditary Factor VIII deficiency

Day 30 discussion

Haematology-Hemostaseology

3.2.3. Split influenza virus, inactivated containing antigen equivalent to A/ California/7/2009(H1N1)-like strain (A/California/7/2009), adjuvanted - EMEA-C-000669-PIP01-09-M02

Sanofi Pasteur SA; Influenza

Day 30 discussion

Vaccines

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Semaglutide - EMEA-001441-PIP02-15-M02

Novo Nordisk; Type 2 Diabetes Mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.2. Obeticholic Acid - Orphan - EMEA-001304-PIP02-13-M04

Intercept Pharma Ltd.; Primary Biliary Cholangitis (PBC) / Biliary Atresia

Day 30 discussion

Gastroenterology-Hepatology

3.3.3. Potassium chloride / sodium chloride / ascorbic acid / sodium ascorbate / sodium sulfate / polyethylene glycol 3350 - EMEA-001705-PIP02-15-M02

Norgine Limited; Bowel cleansing prior to clinical procedures

Day 30 discussion

Gastroenterology-Hepatology

3.3.4. Rilpivirine (as hydrochloride) - EMEA-000317-PIP01-08-M11

Janssen-Cilag International NV; Treatment of human immunodeficiency virus type 1 (HIV-1) infection / Rilpivirine is indicated in combination with other antiretroviral (ARV) medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in ARV-naïve paediatric patients from 2 to less than 18 years with a baseline viral load below 100,000 HIV-1 RNA copies/mL.

Day 30 discussion

Infectious Diseases

3.3.5. 2-Iminobiotin - Orphan - EMEA-001070-PIP01-10-M01

Neurophyxia B.V.; Perinatal asphyxia / Treatment of perinatal asphyxia

Day 30 discussion

Neonatology - Paediatric Intensive Care

Eisai Europe Limited; Treatment of treatment-resistant epilepsies / Adjunctive therapy in patients with other paediatric epilepsies, Adjunctive therapy in patients with refractory partial onset seizures including secondarily generalised seizures

Day 30 discussion

Neurology

3.3.7. Atezolizumab - EMEA-001638-PIP01-14-M02

Roche Registration GmbH; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) / Treatment of paediatric patients from birth to less than 18 years old with a PD-L1 positive paediatric solid tumour as part of the first line treatment

Day 30 discussion

Oncology

3.3.8. lisocabtagene maraleucel (Autologous CD4+ and CD8+ T cells expressing a CD19-Specific Chimeric Antigen Receptor) - Orphan - EMEA-001995-PIP01-16-M02

Celgene Europe B.V.; Treatment of B-lymphoblastic leukemia/lymphoma, Treatment of mature B-cell neoplasms / Treatment of paediatric patients with CD19+ relapsed or refractory B-cell acute lymphoblastic leukaemia, Treatment of paediatric patients with CD19+ relapsed or refractory diffuse-large B-cell lymphoma, Burkitt lymphoma or primary mediastinal large B-cell lymphoma

Day 30 discussion

Oncology

3.3.9. Daratumumab - Orphan - EMEA-002152-PIP01-17-M01

Janssen-Cilag International NV; Treatment of lymphoid malignancies (except mature B-cell neoplasms) / Treatment of paediatric patients from birth to less than 18 years of age with a lymphoid malignancy (except mature B-cell neoplasms)

Day 30 discussion

Oncology

3.3.10. Ibrutinib - Orphan - EMEA-001397-PIP03-14-M04

Janssen-Cilag International N.V.; Treatment of mature B-cell neoplasm / Treatment of children from 1 year to less than 18 years of age with newly-diagnosed and relapsed/refractory mature B-cell lymphoma, that is, diffuse large B-cell lymphoma or Burkitt and Burkitt-like lymphoma.

Day 30 discussion

Oncology

3.3.11. Isatuximab - Orphan - EMEA-002205-PIP01-17-M01

Sanofi-Aventis Recherche & Développement; Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue / Treatment of relapsed, refractory and newly-diagnosed acute lymphoblastic leukemia in combination with standard treatment in paediatric patients from 28 days to less than 18 years of age, Treatment of relapsed, refractory and newly-diagnosed acute myeloid leukemia in combination with standard treatment in paediatric patients from 28 days to less than 18 years of age

Day 30 discussion

Oncology

3.3.12. Lenvatinib - EMEA-001119-PIP02-12-M05

Eisai Europe Ltd; Treatment of papillary thyroid carcinoma, Treatment of Osteosarcoma, Treatment of follicular thyroid carcinoma / Treatment of refractory or relapsed osteosarcoma in children and adolescents, Treatment of progressive, radioiodine-refractory differentiated thyroid cancer in children and adolescents

Day 30 discussion

Oncology

3.3.13. Palbociclib - EMEA-002146-PIP01-17-M01

Pfizer Europe MA EEIG; Treatment of Ewing sarcoma / treatment of refractory or recurrent Ewing sarcoma

Day 30 discussion

Oncology

3.3.14. Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence - Orphan - EMEA-001765-PIP02-15-M03

Orchard Therapeutics (Europe) Ltd; Metachromatic leukodystrophy (MLD) / For the treatment of metachromatic leukodystrophy (MLD)

Day 30 discussion

Other

3.3.15. Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) - Orphan - EMEA-001370-PIP02-13-M02

MolMed S.p.A.; adjunctive treatment in haematopoietic cell transplantation

Day 30 discussion

Other / Haematology-Hemostaseology

3.3.16. Aqueous extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae - EMEA-000815-PIP01-09-M01

Allergy Therapeutics (UK) Ltd; Allergic rhinitis and Acute atopic conjunctivitis due to house dust mites / allergic rhinitis/allergic conjunctivitis

Day 30 discussion

Pneumology - Allergology

3.3.17. Birch, Hazel and Alder Pollen Extract - EMEA-000808-PIP01-09-M01

Allergy Therapeutics (UK) Ltd; J.30.1 Allergic rhinitis due to pollen H10.1 Acute atopic conjunctivitis / Allergic rhinitis/allergic conjuctivitis

Day 30 discussion

Pneumology - Allergology

3.3.18. Vortioxetine - EMEA-000455-PIP02-10-M05

H. Lundbeck A/S; Major Depressive Disorder

Day 30 discussion

Psychiatry

3.3.19. Fc- and CDR-modified humanized monoclonal antibody against C5 - Orphan - EMEA-001943-PIP01-16-M02

Alexion Europe SAS; Atypical Haemolytic Uremic Syndrome / Treatment of atypical Haemolytic Uremic Syndrome

Day 30 discussion

Uro-nephrology / Haematology-Hemostaseology

4. Nominations

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure DD Month 20XX for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

No items.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.2. Ongoing Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.3. Final Scientific Advice (Reports and Scientific Advice letters)

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. Cetuximab-IRDye 700DX Conjugate - EMEA-01-2019

Rakuten Aspyrian, Inc.; The class of Her- / Epidermal growth factor-receptor antibody medicinal products for treatment of head and neck epithelial malignant neoplasms and the class of photosensitising medicinal products for treatment of head and neck epithelial malignant neoplasms/ Treatment, in combination with a PIT690 Laser System, of patients with locoregional recurrent head and neck squamous cell carcinoma (HNSCC) with progressive disease on or after two or more lines of therapy

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was not confirmed since this is a novel product and the class waiver list does not include drug-device combinations.
Other potential paediatric interests of this medicine suggested by PDCO: None at this stage.

6.1.2. Leuco-methylthioninium bis(hydromethanesulfonate) - EMEA-04-2019

TauRx Therapeutics Europe Ltd.; All classes of medicinal products for treatment of Alzheimer's disease / Treatment of early/mild/moderate Alzheimer's Disease

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.
Other potential paediatric interests of this medicine suggested by PDCO: None at this stage.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

No items

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

No items

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The PDCO members were informed about the final CHMP opinions on medicinal products with recommended paediatric indications adopted in February 2019. These included Dectova (zanamivir), Dupixent (dupilumab) and Viread (tenofovir disoproxil). Viread granules 33 mg/g were introduced to include use in paediatric patients aged from 2 to less than 12 years of age.

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in February 2019, was presented to the PDCO members.

9.2.2. Committee for Medicinal Products for Human Use (CHMP)

CHMP/PDCO joint session

Summary of committee discussion:

A joint session CHMP/PDCO was held.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of committee discussion:

The Chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group (NCWG) evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require Formulation Working Group evaluation and discussion.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA): Introduction to activities of PEDMED-NL

Summary of committee discussion:

Tessa van der Geest presented an overview of Pedmed-NL (the former Dutch Medicines for Children Research Network) and the activities the network is involved in. The network has been involved in the development of the Dutch Paediatric Formulary (kinderformularium), the establishment of European Paediatric Translational Research Infrastructure (EPTRI) and Paediatric Clinical Research Infrastructure (PEDCRIN) as well as in the planning of clinical trials, mainly via Connect4Children (C4C). These activities were described as the "pharmacotherapy improvement cycle", spanning from "best evidence dose" over translational research to clinical studies. The network was relaunched in 2018 as Pedmed-NL with the main goal to facilitate and support the conduct of C4C proof of viability studies (by 2023). The main goal beyond 2023 is to create a sustainable network for research in children.

9.4.2. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA): Update on outcome of Working Group on Trial Preparedness

PDCO member: Angeliki Siapkara

Summary of committee discussion:

The Committee discussed some wording improvements in the trial preparedness document following a review by the members.

9.4.3. Handling of confidential information within the EU network

Summary of committee discussion:

The PDCO was informed of the best practice for sharing information within the EU network and of the recommended tools to safeguard the confidentiality of the shared information.

9.5. Cooperation with International Regulators

9.5.1. Report from the Paediatric Cluster Teleconference

Summary of committee discussion:

The Committee was informed about the discussions at the Paediatric Cluster teleconference on 21 March 2019.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

9.6.1. Cardiac Safety Research Consortium Think Tank: NOAC Use in the Paediatric Population: Defining the Path Forward - ACC Heart House - Washington, DC – Agenda

PDCO: Dirk Mentzer (Chair)

Summary of committee discussion:

The Committee endorsed the remote participation of Dirk Mentzer, as PDCO Chair, to the upcoming meeting on non-vitamin K antagonist oral anticoagulants (NOAC) Use in the Paediatric Population, organised by the Cardiac Safety Research Consortium. Feedback from the meeting will be provided during the next PDCO plenary.

9.6.2. Outcome of the WHO/Paediatric HIV Vatican Meeting

Summary of committee discussion:

The Committee adopted a letter to WHO summarising some principles considered during the evaluation of PIPs for human immunodeficiency viruses (HIV) medicines.

9.7. PDCO work plan

No items

9.8. Planning and reporting

10. Any other business

No items

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The group discussed the upcoming 4th Paediatric Strategy Forum (Paediatric Strategy Forum for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents). Additionally, the group discussed topics related to currently ongoing paediatric oncology procedures.

11.1.2. Neonatology

Summary of committee discussion:

The Neonatology breakout session discussed PIPs concerning drug development in neonates. The breakout session also discussed the risk of increased mortality after light

exposure of parenteral nutrition and agreed that this potential signal could merit assessment by the PRAC.

11.1.3. Inventory

Summary of committee discussion:

The group convened in the margins of the PDCO plenary meeting to discuss the best approach to capture the Committee's discussion on unmet needs in the minutes of the procedures.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 26-29 March 2019 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting When not chairing the meeting: No participation in final deliberations and voting	2.1.12. Humanized antibody targeting B cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F - Orphan - EMEA-002468-PIP02-18 (D60 opinion) 3.1.28. Human immunoglobulin G2 isotype antibody to IL-33R - EMEA-002515-PIP01-18 (D30 discussion)
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Petra Dominikova	Alternate	Czech Republic	No interests declared	
Kirstine Moll Harboe	Member	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Ann Marie Totterman	Member	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Sigita	Member	Lithuania	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Burokiene				
Goda Vaitkeviciene	Alternate	Lithuania	No interests declared	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Maaike van Dartel	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Ninna Gullberg	Member	Sweden	No interests declared	
Eva Agurell	Alternate	Sweden	No interests declared	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No interests declared	
Jorrit Gerritsen	Alternate	Healthcare Professionals' Representative	No interests declared	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Catherine Cornu	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Doina Plesca	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Günter Karl-Heinz Auerswald	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Michal	Member	Patients'	No restrictions	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Odermarsky		Organisation Representative	applicable to this meeting	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Tessa van der Geest	Expert - in person*		No interests declared	
Nithyanandan Nagercoil	Expert - in person*	MHRA	Direct interests declared	
John Johnston	Expert - via telephone*	MHRA	No interests declared	
Ita Walsh	Expert - via telephone*	Netherlands - CBG/MEB	No interests declared	
Peter Mol	Expert - via telephone*	Netherlands - CBG/MEB	No interests declared	
Mogens Westergaard	Expert - via telephone*	Denmark - DMA	Direct interests declared	
Anja Schiel	Expert - via telephone*	Norway - NOMA	No interests declared	
Jacqueline Kerr	Expert - via telephone*	Germany - PEI	No interests declared	
Andrea Laslop	Expert - in person*	Austria - AGES	No interests declared	
Alexandre Moreau	Expert - in person*	France - ANSM	No interests declared	
Jan Mueller Berghaus	Expert - in person*	Germany - PEI	No interests declared	
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the Applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website:
www.ema.europa.eu/